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ABSTRACT 
 
Background: Disseminated intravascular coagulopathy is a consumption coagulopathy which 
mostly results from an underlying disease. It occurs as a result of the activation of the coagulation 
cascade leading to the formation of thrombi which results in haemorrhage due to the excessive 
consumption of platelet and coagulation factors. Malignancy is associated with hypercoagulable 
state and increased risk for thrombohemorrhagic complications and leukaemia is no exception. 
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Bleeding manifestations are common in acute leukemias, especially in acute myeloblastic 
leukemia, and are prominent features of an initial stage of the disease. This study assessed 
disseminated intravascular coagulopathy (DIC) in leukaemia patients in Nigeria.  
Materials and Methods: One hundred and sixteen (116) subjects consisting of 58 leukaemic 
subjects (AML, CLL, and CML) and 58 age and sex-matched healthy control subjects were 
recruited into the study. The parameters estimated in this study were packed cell volume (PCV), 
platelet count, white blood cell count (WBC), prothrombin time (PT), the international normalised 
ratio (INR), activated partial thromboplastin time (aPTT) and D-dimer assay. 
Results: The mean ± SD values of the parameters assessed in the leukaemia patients include 
3.7±3.1 µg FEU/mL, 67.5±55.7 seconds, 1.8±0.1, 77.3±31.8 seconds, 194±103 cells/mm3, 74±124 
cells/mm
3
, 30±5% for D-dimer, PT, INR, aPTT, platelets, WBC and PCV respectively. The results 
display a significant statistical difference between the leukaemic and the control subjects (p<0.05).  
Conclusion: The abnormality of these haemostatic parameters occurring in the leukaemic 
subjects (AML, CLL, and CML) is highly indicative of the occurrence of disseminated intravascular 
coagulopathy in these patients. This study, therefore, shows that disseminated intravascular 
coagulopathy can occur as a complication of various types of leukaemia studied and this requires 
prompt and appropriate management. 
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1. INTRODUCTION 
 
Disseminated Intravascular Coagulation (DIC) is 
an abnormality characterized by the systemic 
intravascular activation of the coagulation 
system, simultaneously causing intravascular 
thrombi, distorting adequate blood supply to the 
organs, and bleeding as a result of exhaustion of 
the platelets and coagulation factors [1]. The 
clinical characteristics of DIC include 
spontaneous or induced bleeding complications 
and thrombotic complications, whereas multiple 
organ failures may be in part a complication of 
intravascular fibrin formation. Also, the 
generation of multiple proteolytically active 
enzymes of the clotting cascade may escalate 
inflammatory activity, which may increase the 
systemic inflammatory syndrome [2]. 
 
Various disorders including infections or 
inflammatory conditions and malignant disease 
can cause activation of coagulation. In several 
cases, this activation of coagulation may not 
cause clinical complications and may not even 
be detectable by routine laboratory analysis [3]. 
However, if activation of coagulation is 
sufficiently strong, a reduction in platelet count 
and extension of global clotting time may 
become evident [3]. The management of DIC is 
mainly directed at treating the underlying 
disease, but supportive care may be essential. 
This care may involve supplementing the 
platelets, reduced coagulation factors and 
endogenous coagulation inhibitors, inhibiting 
coagulation by different anticoagulant strategies 
and/or by exploiting the fibrinolytic system [4]. 
DIC could be initiated as a result of a 
complication of some neoplastic diseases such 
as leukaemia and myeloproliferative disorders. 
Leukaemia is a group of malignancies that 
normally starts in the bone marrow and causes 
the production of raised numbers of abnormal 
white blood cells [5]. Leukaemia can be generally 
classified as acute or chronic and can 
additionally be classified as myeloid or lymphoid 
depending on the cell line that is affected. The 
cause of leukaemia remains unidentified, 
however, a higher risk is associated with certain 
substances (e.g. benzene), large doses of 
ionizing radiation and infection with specific 
viruses (e.g., Epstein-Barr virus, human 
lymphotropic virus). Smoking cigarettes and 
exposure to electromagnetic fields also have 
been suggested as predisposing factors [6].  
 
Of various forms of leukaemias, acute 
promyelocytic leukaemia (APL), a subtype of 
acute myeloid leukaemia (AML), has been 
associated with multiple haemostatic 
abnormalities [7]. Most, if not all, patients with 
APL have signs of DIC at the time of diagnosis. 
Patients with APL have an increased risk of 
death during initiation therapy when compared 
with patients with other forms of leukaemia, 
mostly due to bleeding. Unfortunately, outside of 
clinical trials, the rate of early death in APL has 
not changed with the advent of new therapies [8]. 
Disseminated intravascular coagulopathy is a 
critical clinical condition and has been 
demonstrated in some individuals with acute 
leukaemia [9]. There is a paucity of information 
on the presence of disseminated intravascular 
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coagulopathy in different types of acute 
leukaemia and other forms of chronic leukaemia 
in this environment. It is, therefore, necessary to 
investigate DIC in individuals with different forms 
of leukaemia treatment for the possibility of 
management of DIC alongside leukaemia in such 
situations.  
 
2. MATERIALS AND METHODS 
 
2.1 Subject Selection 
 
Fifty-eight (58) patients comprising of 30 females 
and 28 males with acute myeloblastic leukaemia 
(AML), chronic lymphocytic leukaemia (CLL) and 
chronic myelocytic leukaemia (CML) who were 
newly diagnosed and at initial stage of 
chemotherapy were recruited over a period of 8 
months from the Federal Teaching Hospital, Ido–
Ekiti, Nigeria and other specialist medical centres 
around while additional fifty-eight (58) age-sex 
matched healthy individuals served as control 
subjectsin this study. The patients distribution 
consist of 32 CLL, 24 CML and 2 AML patients 
with no patient with acute lymphocytic leukaemia 
(ALL) presented in the hospital during the patient 
recruitment period. Ethical approval and informed 
consent were obtained from the Federal 
Teaching Hospital Ido-Ekiti, and Ekiti State 
University Teaching Hospital health research 
committees and the participants respectively. 
 
2.2 Blood Samples Collection and 
Analysis  
 
Four millilitres (4 ml) of peripheral blood was 
collected from each participant with 2 mls 
dispensed into the 0.25 ml of trisodium citrate 
anticoagulant (anticoagulant, blood ratio, 1:9) for 
the coagulation studies; 2 mls dispensed into 
EDTA contained vials for the complete blood 
count. The citrated blood for coagulation studies 
was separated by centrifugation at 1500 rpm for 
15 minutes to obtain platelet-rich plasma which 
was stored frozen at – 20°C until analysed. 
 
The parameters estimated and their 
corresponding methods of analysis used in this 
study were packed cell volume, platelet and 
white blood cell counts using Abacus junior 
haematological autoanalyser; prothrombin time 
(PT), international normalised ratio (INR), 
activated partial thromboplastin time (aPTT) 
using Diagen reagents; D-dimer assay using 
Tina Quant Gen 2 D-dimer reagent on Roche 
Cobas C 111 analyser by immunoturbidometry 
technique. 
2.3 Statistical Analysis 
 
The data generated were expressed as mean ± 
SD. A p-value < 0.05 was considered the 
significant levels of the statistical analysis using 
SPSS version 20. 
 
3. RESULTS 
 
The results of this study show 30 female and 28 
male leukaemic subjects out of which thirty-two 
(32) subject had CLL, twenty-four subjects (24) 
had CML and two (2) subjects had AML. They 
aged between 35 and 65 years. The mean±SD 
values of various parameters estimated in all 
participants involved in this study are 
represented in Table 1. This reflects a significant 
difference in the clotting times between the 
patients when compared with the control subjects 
(p<0.05). Platelet counts however reduced in the 
patients than the control subjects though not 
statistically significant.  
 
Additionally, the PT and aPTT distribution among 
the D-dimer level in the leukaemic subjects is 
represented in Table 2. It was observed that fifty 
(86%) of the patients had increased D-dimer and 
prolonged PT while forty-eight (82%) had 
increase D-dimer and prolonged PTTK with five 
(9%) having a prolonged PT, aPTT, INR and 
increased D-dimer level. These five (5) subjects 
were also observed to present with 
thrombocytopenia. 
 
The mean ±SD values of PT, aPTT, D-dimer , 
platelet count, PCV and WBC in the female and 
male patients are 81.33±67.39, 83.33±34.09, 
3.78±3.53, 167.93±90.27, 27.93±5.61, 
77.75±139.58 and 52.86±36.64, 70.93±29.01, 
3.69±2.78, 221.14±111.38, 32.07±4.45 and 
77.75±139.58 respectively. This result displays 
no significant difference in the variables except in 
PCV (p=0.03). 
 
4. DISCUSSION  
 
DIC is a dynamic process and the analysis 
performed shows only the conditions at a given 
moment in time [10]. In clinical conditions 
associated with DIC, repeating the tests 
performed initially helps in establishing the 
diagnosis. Analysis performed in assessing the 
haemostatic state give information about the 
clinical course and the diagnosis is established 
based on clinical suspicion and supportive 
laboratory analysis [10]. These assessment 
analyses include laboratory parameters 
indicative of procoagulant and fibrinolytic
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Table 1. Mean±SD of estimated parameters in the leukaemia patients and control subjects 
 
Parameters Patients n=58Mean±SD  Control n=58Mean±SD  t-test p-value 
D-dimer(µg 
FEU/mL) 
3.74±3.13 0.31±0.18 5.888 0.001 
PT(seconds) 67.59±55.71 13.10±1.06 5.266 0.001 
INR 
aPTT(seconds) 
1.84±0.09 
77.34±31.81 
1.11±0.02 
31.19±2.16 
7.705 
7.796 
0.001 
0.001 
Platelet count 
(cells/mm
3
) 
193.62±102.79 233.69±59.34 1.818 0.074 
WBC(cells/mm3) 74±124.42 5.08±1.34 3.506 0.001 
PCV (%) 30.07±5.38 37.80±4.63 5.870 0.001 
Abbreviations= PCV (Packed Cell Volume), WBC (White Blood Cell Count), PT (Prothrombin Time),  
PTTK (Partial Thromboplastin Time with Kaolin), INR (International Normalised Ratio) 
 
substance activation, inhibitor consumption and 
organ damage or failure [11]. 
 
Malignancy is associated with a hypercoagulable 
state and a high risk for thrombohemorrhagic 
complications. Its clinical complications may 
range from localized thrombosis to bleeding of 
varying degrees of severity because of DIC with 
life-threatening bleeding being frequent in acute 
leukemia, particularly in APL [11]. Laboratory 
assessments show a profound hemostatic 
imbalance in this condition, with activation of 
coagulation, fibrinolysis, and nonspecific 
proteolysis systems [11]. 
 
This study evaluated some coagulation 
parameters to assess DIC in leukaemia patients 
and the parameters are; PT, INR, aPTT, platelet 
count, PCV and D-dimer assays. It was observed 
that the patients had a lower PCV (p <0.05) and 
platelet (p >0.05) values when compared with 
values obtained in the control subjects (Table 1) 
and this possibly reflect anaemia of chronic 
disease in the leukemia patients or that of 
cytotoxic therapy being administered. This 
established fact was validated by a previous 
study carried out by Akanni et al. [12] where a 
significantly low PCV was observed in values               
of leukaemic patients when compared with 
controls. 
 
The reduced mean±SD values of platelet count 
(though insignificant when compared with 
control) observed is also suggestive of excessive 
platelet consumption which is indicative of likely  
onset of DIC, resulting in the platelets being 
excessively consumed, hence bleeding. In 2014, 
Sadik et al. [13], reported some similar 
corroborating multicenter meta-analysis studies 
where the researchers specified that the most 
frequently encountered abnormal laboratory 
findings in DIC were thrombocytopenia, 
increased fibrin degradation products, prolonged 
PT, aPTT and low fibrinogen levels [14,15, 
16,17].   
 
The PT, aPTT and INR of the leukaemia patients 
in this study were found to be significantly 
prolonged (p<0.05) than those of the control 
subjects which were within normal range (Table 
1). This is presumably due to the exhaustion of 
some coagulation factors involved in the extrinsic 
pathway along with thrombocytopenia in some of 
the leukaemia subjects which is due to DIC. This 
finding is similar to the report of another study 
carried out among Sudanese by Amr et al. [18], 
where they discovered the leukaemia subjects to 
have prolonged coagulation parameters than 
controls (p<0.05). Sadik et al. [13] also 
concluded in their study that prolonged PT, aPTT 
and INR is a common finding in DIC. 
 
The increased D-dimer level along with the 
prolonged PT/aPTT observed in the leukaemia 
participants in this study indicates increased 
fibrin deposition by coagulation process resulting 
in an increased fibrinolytic activity. Since D-
Dimer is a fibrin degradation product hence an 
increased D-Dimer level is a diagnostic factor of 
DIC. 
 
The sex distribution for the WBC, platelet and the 
haemostatic parameters carried out in this study 
displays an insignificant statistical difference 
between the genders which infers that gender 
has no effects on these parameters measured. 
Expectedly, there was a statistically significant 
difference (p<0.05) in the PCV, suggesting that 
gender plays a major role in the PCV values of 
the subjects. 
 
Furthermore, some patients were observed to 
have both increased D-dimer and prolonged PT 
level while some had both increased D-dimer 
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and prolonged aPTT level (Table 2) indicating 
the likely development of DIC among these 
population. Also, about 9% of the studied 
population have prolonged PT, PTTK, INR, 
increased D-dimer level and thrombocytopenia 
establishing the onset of DIC symptoms which is 
evidenced by some bleeding episodes 
experienced by the patients. This observation is 
corroborated by a study that ascertained the 
prolonged PT/PTTK and D-dimer as diagnostic 
tools for DIC [10]. 
 
Table 2. Distribution of D-dimer levels among 
the PT and aPTT levels in the leukaemia 
subjects 
 
D-dimer (n=58) 
  Normal  High p- value 
PT Normal 0 2 0.731 
 High 6 50  
aPTT Normal 0 4 0.619 
 High 6 48  
PT (Prothrombin Time), PTTK (Partial Thromboplastin 
Time with Kaolin) 
 
5. CONCLUSION 
 
In conclusion, the majority of the haemostatic 
parameters analysed in the leukemic patients 
were observed to be abnormal, with the PT, 
aPTT, INR being very prolonged and D-dimer 
level elevated while the platelet count decreased 
below the normal level (though insignificant) in 
some of the subjects. These trends of results are 
characteristic of DIC and indicative of the 
condition as a result of an impaired haemostatic 
activity in most of the leukemic subjects recruited 
in the study. This study has therefore revealed 
strong evidence of the possibility of DIC in 
individuals suffering from various types of 
leukaemia condition (AML, CLL and CML) 
regardless of their gender and treatment status. 
 
It is therefore recommended that in the 
management and treatment of leukemia patients, 
DIC should be carefully screened and monitored 
in this region as it is being done in the developed 
world health management system. This will 
ensure possible detection of its occurrence at the 
onset and will promote adequate management of 
the disorder. 
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